http://orcid.org/0000-0002-5117-2502
References
- Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. Bmj. 2014;348:g2467.
- Hewitson P, Glasziou P, Irwig L, et al. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev. 2007;(1):Cd001216.
- Fish D, Temple LK. Functional consequences of colorectal cancer management. Surg Oncol Clin N Am. 2014;23:127–149.
- Ahmed S, Johnson K, Ahmed O, et al. Advances in the management of colorectal cancer: from biology to treatment. Int J Colorectal Dis. 2014;29:1031–1042.
- Abdel-Rahman O. Revisiting Dukes’ paradigm; some node positive colon cancer patients have better prognosis than some node negative patients. Clin Transl Oncol. 2017.
- Abdel-Rahman O. Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside. Future Oncol. 2016;12:25–30.
- Jones RP, McWhirter D, Fretwell VL, et al. Clinical follow-up does not improve survival after resection of stage I-III colorectal cancer: a cohort study. Int J Surg. 2015;17:67–71.
- Primrose JN, Perera R, Gray A, et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Jama. 2014;311:263–270.
- Jeffery M, Hickey BE, Hider PN, et al. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2016;11:Cd002200.
- Allemani C, Rachet B, Weir HK, et al. Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study. BMJ Open. 2013;3:e003055.
- Macafee DA, Whynes DK, Scholefield JH. Risk-stratified intensive follow up for treated colorectal cancer - realistic and cost saving? Colorectal Dis. 2008;10:222–230.
- O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on cancer sixth edition staging. J Natl Cancer Inst. 2004;96:1420–1425.
- Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Custom Data (with additional treatment fields), Nov 2016 Sub (1973-2014 varying) - Linked To County Attributes - Total U.S., 1969-2015 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released 2017 Apr, based on the November 2016 submission.
- Battersby NJ, Coupland A, Bouliotis G, et al. Metachronous colorectal cancer: a competing risks analysis with consideration for a stratified approach to surveillance colonoscopy. J Surg Oncol. 2014;109:445–450.
- Gao XH, Yu GY, Gong HF, et al. Differences of protein expression profiles, KRAS and BRAF mutation, and prognosis in right-sided colon, left-sided colon and rectal cancer. Sci Rep. 2017;7:7882.
- Maccaroni E, Bracci R, Giampieri R, et al. Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: are all mutations equal? Oncotarget. 2015;6:38737–38748.
- Benson AB 3rd, Venook AP, Cederquist L, et al. Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15:370–398.
- Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi64–72.
- Andre T, Iveson T, Labianca R, et al. The IDEA (international duration evaluation of adjuvant chemotherapy) collaboration: prospective combined analysis of phase iii trials investigating duration of adjuvant therapy with the FOLFOX (FOLFOX4 or modified FOLFOX6) or XELOX (3 versus 6 months) regimen for patients with stage III colon cancer: trial design and current status. Curr Colorectal Cancer Rep. 2013;9:261–269.